Friedewald's formula which cannot be used in the postprandial samples. Although the homogeneous assays with poor analytical performance were withdrawn from the market, it remained unclear whether the currently available reagents for LDL-C and high-density lipoprotein-cholesterol (HDL-C) are as accurate for postprandial samples as for fasting samples. Methods: Fresh blood samples were collected from 59 non-diseased and 109 diseased subjects. Postprandial samples constituted 72.9% and 39.4% of these samples. LDL-C and HDL-C concentrations were measured using the homogeneous assays of four manufacturers (Denka Seiken, Wako, Kyowa Medex, and Sekisui Medical). Simultaneously, LDL-C and HDL-C concentrations were determined using the reference measurement procedures (RMPs) of the Centers for Disease Control and Prevention (CDC). Total errors were calculated using a routine method (TEcom) and via error component analysis (TEECA). Results: All homogeneous assays for LDL-C and HDL-C met the National Cholesterol Education Program (NCEP) requirements in terms of coefficient of variation, and TEcom in both non-diseased and diseased subjects. LDL-C and HDL-C values measured by the homogeneous assays were in good agreement with those measured by the RMPs in both fasting and postprandial samples. The TEcom and TEECA values of the postprandial samples were similar to those of fasting samples, although the TEECA values were up to 4.4-fold greater than the TEcom values. Conclusions: In both non-diseased and diseased subjects, the homogeneous assays for LDL-C and HDL-C of four manufacturers are as accurate for postprandial samples as for fasting samples.
Introduction
The homogeneous assays for low-density lipoCopyright©2017 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
at Osaka University Hospital (Osaka, Japan) and the National Cerebral and Cardiovascular Center (NCVC, Osaka, Japan). Both normolipidemic and dyslipidemic subjects were eligible provided that their lipoprotein concentrations were in a certain range [20 mg/dL ≤ LDL-C; 20 mg/dL ≤ HDL-C 100 mg/dL; TG 1,000 mg/dL]. In line with the exclusion criteria of our previous studies 5, 6) , we did not enroll patients with serious infectious diseases, decompensated liver cirrhosis, or cholestatic liver diseases. A diagnosis of hyperlipidemia was made if the LDL-C level was 160 mg/dL, and/or the TG level 200 mg/dL, under conditions of ad libitum food intake. Normolipidemic subjects with no medical history were classified as non-diseased, whereas others were considered diseased. This study complied with the dictates of the latest version of the Declaration of Helsinki (thus, that amended at the 64th WMA General Assembly, Fortaleza, Brazil, October 2013 12) ). At recruitment, written informed consent was obtained from all participants. The study protocol was approved by the Ethics Committees of the individual institutions.
Study Protocol
Fresh venous blood was drawn and serum was collected after centrifugation, dispensed into screwcapped tubes, and immediately stored at 4 . The next morning, an aliquot of each sample was conveyed to the Kyoto Prefectural University where LDL-C and HDL-C were measured using homogeneous assays. The remaining samples were subjected (at NCVC) to LDL-C and HDL-C measurements using the RMPs described below. During sample transport, we used a special cooling container that held the samples at 2 -4 (without freezing) 5) . All measurements were performed on the day of sample arrival.
Assays for LDL-C and HDL-C
At Kyoto Prefectural University, we measured LDL-C and HDL-C concentrations using four homogeneous assays [LDL-CHA and HDL-CHA]. The reagents were manufactured by Denka Seiken, Wako, Kyowa Medex, and Sekisui Medical (Supplemental Table 1 ). All reagents, calibrators, and controls were provided by these companies. All reagents except the reagent of Kyowa Medex (used in the LDL-C assay) were the same as those described in our previous studies 5, 6) . The Kyowa Medex reagent (MetaboLead LDL-C) was a modified version of the previous formulation (Determiner L; LDL-C). The newer version exhibits an improved specificity for LDL particles; interference by TG-rich lipoproteins is reduced. TG concentrations were determined using an enzymatic method.
We employed the same automated analyzer used assay time [1] [2] [3] [4] . Other strengths of such assays are excellent intra-and inter-assay reproducibility. These assays are also termed direct methods. To date, several original reagents have been developed in Japan by different manufacturers, based on various principles. Latecomer companies (distributors) purchase bulk reagents from the original manufacturers, and sell their products with different brand names 5, 6) . To ensure global standardization and harmonization of lipid laboratory tests, the Centers for Disease Control and Prevention (CDC) runs a manufacturer certification program with the aid of the Cholesterol Reference Method Laboratory Network (CRMLN) 7) . All commercial homogeneous assays produced by the original manufactures and their distributors have taken part in this program, and have passed the precision and accuracy requirements defined by the National Cholesterol Education Program (NCEP) 8, 9) . Despite these efforts, earlier studies revealed that some homogenous assays exhibited poor analytical performance in patients with common diseases, and even in disease-free subjects 5, 6, 10, 11) . At the end of 2016, these reagents were withdrawn from the Japanese market. A common problem was that when these reagents were used, hypertriglyceridemia often triggered a positive assay bias, especially in LDL-C measurements 5, 10) . In contrast to the LDL-C estimations afforded by various equations, homogeneous assays are applicable to postprandial samples with triglyceride (TG)-rich lipoprotein levels greater than those of the fasting state. However, no study has yet directly compared the accuracy of homogeneous assays of fasting samples with those of postprandial samples using the reference measurement procedures (RMPs) of the CDC, employing fresh sera collected from non-diseased and diseased subjects.
Aim
Our aim was to clarify whether homogeneous assays for LDL-C and HDL-C are as accurate for postprandial samples as for fasting samples.
Methods

Study Subjects
Study participants were volunteers and outpatients els, and measurement of cholesterol concentrations in both 
Determination of Precision Using Pooled Sera
We prepared the pooled sera, dispensed the pool into screw-capped tubes, and stored the tubes at 80 . After thawing, we measured LDL-C and HDL-C concentrations using all of the homogeneous assays (Supplemental Table 1 ) 30 times within a single day to determine among-run coefficients of variance (CVs), and on 21 different days to determine between-run CVs. Bias was assessed by subtracting the LDL-CRMP (or HDL-CRMP) from the LDL-CHA (or HDL-CHA). Bias percentages were calculated as (bias/LDL-CRMP or HDL-CRMP) 100.
Statistical Analysis
We calculated two different total errors (TEcom in previous studies (Hitachi-7170; overseas brand name Hitachi-917) 5, 6) . We prepared all reagents for the homogeneous assays in a defined order, and measured LDL-C, HDL-C, and TG concentrations once in each cycle. We repeated this process three times, yielding triplicate measurements. These procedures were the same as employed in earlier studies 5, 6, 10, 11) . At NCVC, LDL-C and HDL-C concentrations were measured using the RMPs [LDL-CRMP and HDL-CRMP] employed by the CRMLN 5, 6) . In brief, the top fraction of ultracentrifuged serum (d 1.006, 18 , 105,000 g , 18.5 h), which contained VLDL and chylomicrons, was separated from the bottom fraction, which contained LDL and HDL. The volume of the bottom fraction was adjusted to the original volume (5 mL) with 0.15 mol/L NaCl (Fraction 1). Then, a precipitate was obtained by addition of 40 µL of a heparin solution (5,000 units/mL) and 50 µL MnCl2 (1.0 mol/L). The supernatant (Fraction 2, containing only HDL) was recovered after centrifugation of this mixture. After adjusting both volumes to the baseline lev- [ECA] and CVECA differ from the %bias and betweenrun CV used to calculate the conventional TEcom. We evaluated the CVs and TEs as dictated by the NCEP (Supplemental Table 2 ) 8, 9) .
Results
Background of Study Participants
We collected fresh blood samples from 183 subjects. A total of 15 samples were excluded on the basis of the exclusion criteria, and/or because some essential data were missing. Finally, 59 non-diseased and 109 diseased participants were selected for further analysis (Supplemental Fig. 1) . Those in the diseased group had common diseases treated in the outpatient clinic, although one patient had type hyperlipidemia and one a lipoprotein lipase deficiency ( Table 1) . More than half the samples were obtained in the postpranand TEECA). TEcom was defined as |bias (%)| 1.96 between-run CV (%) 14) . For error component analysis, we followed the modified methods of Nilsson 15) . The details have been described elsewhere 5) . Briefly, error component analysis is based on the hypothesis that analytical errors are derived from three components: the inter-assay CV (CVb), the intra-assay CV (CVe), and a CV derived from sample-specific effects (CVd). CVECA was calculated as the square root of [(CVb) 2 (CVe) 2 (CVd) 2 ] where CVb equals the between-run CV of the logtransformed data from the pooled sera. We also calculated the mean bias [ECA], the among-run CV (CVe), and the subject-specific CV (CVd), using the log-transformed LDL-CRMP and LDL-CHA, or HDL-CRMP and HDL-CHA of fresh samples. From these log-transformed variations, TEECA was defined as |bias [ECA] (%)| 1.96 CVECA (%). It should be noted that the %bias HDL-C surpassed the 95% acceptance criterion when fasting and postprandial samples were assayed together ( Table 2) . Little difference in analytical performance was evident between fasting and postprandial samples.
In the diseased group, the LDL-C reagents fulfilled the NCEP TE requirements in 90 -95% of samples. The HDL-C reagents made by manufacturers B, C, and D met the acceptance criteria when used to assay all samples, independent of fasting status.
3) Comparison of Fasting and Postprandial Samples
For all reagents, the LDL-CHA concentrations agreed well with the LDL-CRMP concentrations in both fasting and postprandial samples, whether or not the subjects were diseased. In scatter plots, the postprandial data (Fig. 2 , red circles) were well-superimposed on the fasting data ( Fig. 2, yellow circles) . Bland-Altman plots indicated an absence of systematic errors in the LDL-CHA concentrations. Similar findings were observed when fasting and postprandial HDL-CHA levels were assayed. In both the non-diseased and diseased groups, the postprandial data were compatible with the fasting data (Fig. 3) .
As in previous studies, we combined the data from fasting and postprandial subjects and evaluated the analytical performance of the LDL-C and HDL-C assay reagents using the TEECA approach. In addition, we calculated TEcom values to allow additional comparisons. For both LDL-CHA and HDL-CHA, the TEcom values were much lower than the NCEP TE requirements (LDL-C, ≤12%; HDL-C, ≤13%) for all reagents ( Table  3) . The maximum TEcom values were about 7% for both LDL-CHA and HDL-CHA. On the other hand, the TEECA was 1.1 -3.6-fold greater than the TEcom in the non-diseased group, and 1.4 -4.4-fold greater in dial state. The samples exhibited wide ranges of TG, LDL-C, and HDL-C concentrations (Supplemental Table 3 ). In the diseased group, 7.3% of patients had TG levels 400 mg/dL.
Precision of the Homogeneous Assays
Upon analyses of pooled sera, the homogeneous assays for LDL-CHA and HDL-CHA exhibited excellent reproducibilities. For all reagents, the among-run CVs for LDL-CHA and HDL-CHA were less than 1%. The between-run CVs for LDL-CHA and HDL-CHA were about 1.0% (Supplemental Table 4 ), lower than the acceptable imprecisions of the NCEP (LDL-C, ≤ 4%; HDL-C, ≤ 4%) (Supplemental Table 2 ).
Accuracies of the Homogeneous Assays 1) Percentage Bias in Triplicate Measurements
Each bias was obtained by subtracting the LDL-CRMP from the mean of the triplicate LDL-CHA, or the HDL-CRMP from the mean of the triplicate HDL-CHA. For all reagents tested, both the non-diseased and diseased groups exhibited very low median %biases for LDL-CHA and HDL-CHA (Fig. 1) . In the non-diseased group, the %biases for LDL-CHA and HDL-CHA lay close to the zero line for all reagents. Most individual %biases were ≤ 12% for LDL-C and ≤ 13% for HDL-C. Even in diseased patients, only a small number of samples (slightly) exceeded these values.
2) TE of Single Measurements
In this analysis, we used the first LDL-CHA or HDL-CHA obtained using triplicate measurements, and determined whether or not the calculated TEs of individual samples fulfilled the NCEP TE requirements. In the non-diseased group, all reagents for LDL-C and 
Discussion
This study indicates that the homogeneous assays for LDL-C and HDL-C from all four manufacturers are as accurate for postprandial samples as for fasting samples. We found that the TEcom values for all reagents were less than 8% for the LDL-C reagents, and less than 9% for the HDL-C reagents, used to assay both fasting and postprandial samples in both the non-diseased and diseased groups ( Table 4) . Scatter plots and Bland-Altman plots showed that none of the homogeneous assays for LDL-C and HDL-C differed in terms of reactivity when used to assay fasting and postprandial samples (Figs. 2 and 3) .
The LDL-C concentration is one of the most important risk markers of cardiovascular diseases, and is recognized as such in many countries [16] [17] [18] [19] [20] [21] [22] . Although the diseased group. With the exception of the reagents of manufacturer C in the non-diseased group, the TEECA values of the LDL-C reagents were greater than those of the HDL-C reagents. Although the TEECA values of all HDL-C reagents met the NCEP TE requirements in both the non-diseased and diseased groups, the TEECA values for the LDL-C reagents fulfilled the NCEP TE requirements only in the non-diseased group. Although the TEECA values of the LDL-C reagents exceeded the cut-offs in the diseased group, the differences between the TEECA values and these cut-offs ranged from 0.76% to 1.84%.
Finally, we separately compared the analytical performances of the homogenous assays used to assess fasting and postprandial samples. Both the TEcom and TEECA values of fasting and postprandial data were very similar for all reagents in both groups (Table 4) . For all reagents, except the LDL-C reagent of manufacturer C, the TEcom and TEECA values were less than onary artery disease, LDL-C and HDL-C concentrations did not increase during the day. Instead, LDL-C and HDL-C decreased by 1.6 to 6.0%, and from 0.0% to 6.0% from the fasting state. These reductions were comparable to that in total cholesterol. Therefore, it is strongly suggested that homogeneous assays for LDL-C and HDL-C are not affected by postprandial increase in TG concentration. These results agree well with those of the present study. To date, only two groups (including our group) have explored the accuracy of homogeneous assays for LDL-C and HDL-C using fresh sera from non-diseased and diseased subjects of various backgrounds 5, 6, 10, 11) . Both groups employed homogeneous assays to measure LDL-CHA and HDL-CHA levels, and also measured LDL-CRMP and HDL-CRMP using the RMPs of the CDC in a single central laboratory of a CRMLN institution. Both groups found that some homogeneous assays were of poor analytical performance 5, 6, 10, 11) . These studies prompted the manufacturers and distributors to withdraw defective reagents from the Japanese market. Therefore, all currently available homogeneous assays for LDL-C use the four original reagents (examined in the present study) or products derived therefrom. The LDL-C homogeneous assay of Kyowa LDL-C concentrations are often calculated using Friedewald's formula 23) , the accuracy depends on the TG concentration 24) . This is attributable to an increase in chylomicron levels 25) , and compositional changes of TG-rich lipoproteins, in patients with hypertriglyceridemia 24, 26) .
To overcome these problems, several modified equations have been proposed by different groups 24, [27] [28] [29] [30] [31] [32] . However, most methods, including that of Friedewald, require subjects to fast overnight to exclude a negative bias in LDL-C measurements [27] [28] [29] [30] [31] [32] [33] . In clinical practice, it is sometimes difficult to obtain fasting samples. For example, almost 90% of patients with acute coronary syndrome (ACS) have not fasted for a sufficiently long period to allow LDL-C levels to be calculated 34) . In outpatients with diabetes mellitus, postprandial samples are preferred, because postprandial hyperglycemia and hyperlipidemia are established risk factors for atherosclerotic disorders [35] [36] [37] [38] [39] . Homogeneous assays are useful to determine the lipid profiles of postprandial patients.
In our previous study, we examined circadian changes in LDL-C and HDL-C concentrations determined by the homogeneous assays 40) . Although the mean TG concentration increased by 20.9% in the control group, and by 30.9% in the patients with cor- LDL-C, low-density lipoprotein-cholesterol; CV, coefficient of variance; HDL-C, high-density lipoprotein-cholesterol; HA, homogeneous assay Data in each cell are the calculated values for fasting (left) and postprandial (right) samples. All parameters were calculated as described in the legend to Table 3 . A, Denka Seiken; B, Wako; C, Kyowa Medex; D, Sekisui Medical crete distributions. All previous publications, including ours 5, 6, 10, 11) , that employed the MSSD violated this continuity assumption (Supplemental Table 2 ). From the equation above, as the TE is a quadratic function of the MSSD, the TEECA is usually higher than the TEcom if the distributions are discrete. As shown in Table 3 , this is in line with the fact that the TEcom and TEECA exhibited large discrepancies, although conventional assessments of LDL and HDL measurement accuracies were in the permissive ranges.
We should be aware that most epidemiological and clinical studies have used Friedewald's formula for LDL-C estimation although there are several methods to measure LDL-C concentrations. In the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), the first study to demonstrate the significant reduction in coronary artery disease by LDL-C lowering with cholestylamine, LDL-C concentrations were determined by ultracentrifugation and subsequent precipitation of apoB-containing lipoproteins 43) . The CDC's RMP of LDL-C measurement is based on this method with some modifications. In the early clinical trials with statins such as the West of Scotland Coronary Prevention Study (WOS-COPS) 44) and the Scandinavian Simvastatin Survival Study (4S) 45) , LDL-C concentration was measured by the method of the LRC-CPPT 43) . Subsequently, many clinical trials and cohort studies used Friedewald's formula for LDL-C estimation. After the development of homogeneous assays in the late 1990s, some clinical trials including the Management of Elevated cholesterol in the primary prevention Group of Adult Japanese (MEGA) Study 46) , the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial 47) , and the Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus Atorvastatin (SATURN) 48) , LDL-C concentrations were determined basically by the Friedewald's formula, but by the homogeneous assays when TG concentrations exceeded 300 or 400 mg/dL. More recently, some clinical and epidemiological studies used a homogeneous assay as the only method to measure LDL-C concentration [49] [50] [51] [52] [53] . Therefore, we need to accumulate more evidence that LDL-C concentration determined by homogeneous assays is a significant predictor of cardiovascular diseases.
We conclude that the homogeneous assays for LDL-C and HDL-C available from four manufacturers are as accurate for postprandial samples as for fasting samples. Although our series of studies on homogeneous assays has encouraged the withdrawal and improvement of reagents exhibiting poor analytical performance, future reagents require extensive preclinical evaluation to avoid unnecessary confusion.
Medex employs a modified version of the prior formulation 5) . Here, this new LDL-C assay was shown for the first time to exhibit satisfactory accuracy. In terms of HDL-C assays, six original reagents (including four examined in the present study) and their derivatives remain on the Japanese market. However, homogenous assays exhibit significant diversity in terms of LDL or HDL reactivities when sera from specific patients with extremely low or high lipoprotein concentrations are assayed, and when sera from those with highly abnormal lipoprotein compositions (such as patients with cholestatic liver diseases) are evaluated 5, 6, 10, 11, 26, 41, 42) . Therefore, homogeneous assays should only be used to screen for dyslipidemia in, and evaluate therapies for, subjects without disease and those with common disorders. The results of our two studies indicate that the reagents tested here in patients with TG concentrations 1,000mg/dL are reliable.
In the present study, we calculated two distinct TE values: TEcom and TEECA. In general, TEcom is used for quality assurance surveillance 14) . Furthermore, TEcom was adopted by the CDC when establishing certification protocols for manufacturers of LDL-C and HDL-C assay reagents [7] [8] [9] . Total error is a concept reflecting precision and accuracy simultaneously. Precision refers to reproducibility upon multiple measurements, whereas accuracy refers to how close the measured values are to the true values 14) . In the present study, the TEcom values of all reagents were much lower than the NCEP requirements (12% for LDL-C and 13% for HDL-C), whether or not the study subjects were fasting or diseased. The TEcom data showed that all tested reagents exhibited satisfactory analytical performance.
It is rather puzzling that the TEECA values were much worse in the study of Miller than in our current work, even though both groups ran error component analysis using similar protocols 5, 6, 10, 11) . We speculate that the measurement errors recorded by Miller et al. 10, 11) might have been accidentally exaggerated for the following reasons. The TEECA is based on the hypotheses that errors are exhibited by the log-transformed variations of three components; CVb, CVe, and CVd. CVd originates from patient-sample-specific effect, and is calculated as the mean square successive difference (MSSD) between the sorted measurement values, as follows:
The major assumption of this equation is that Vi 1 Vi is both very small and continuous 5, 15) . However, not every TEECA based on the MSSD is valid in diseased samples when LDL measurements exhibit dis- Tamio Teramoto) . The authors would like to thank the four Japanese manufacturers mentioned in the Methods section for providing the reagents used in the LDL-C and HDL-C homogeneous assays, calibrators, and controls.
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